Bradley Merrill Thompson Comments on the MEDTECH Act – Media Coverage Roundup

Multiple Publications

Bradley Merrill Thompson, Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in multiple publications regarding the Medical Electronic Data Technology Enhancement for Consumers’ Health (MEDTECH) Act, a bill aimed at limiting FDA regulation of health IT software.

Following is an excerpt from Reuters:

"The act takes a straightforward and clean approach and as a result is less likely to have unintended consequences," added Bradley Merrill Thompson, an FDA-specialist with the Washington D.C.-based legal firm Epstein Becker & Green.

Merrill Thompson said the bill would retain FDA oversight over medium-risk or high-risk software, and technology that serves as an accessory to a medical device. But the bill does not propose any specific body or agency that would be charged with determining levels of risk.

See also:

Bloomberg BNA’s Medical Devices Law & Industry Report, 12/05/2014

The Gray Sheet, 12/05/2014

POLITICO Pro, 12/04/2014

FDA Week, 12/04/2014

Law360, 12/04/2014

FDA Week, 11/28/2014

Inside Health Policy's Inside CMS, 11/27/2014

American Health Line, 11/25/2014

Ortho Spine News, 11/25/2014

Health Data Management, 11/25/2014

mHealth News, 11/25/2014


Inside Health Policy’s New Congress Watch, 11/24/2014

iHealthBeat, 11/24/2014

POLITICO’s Morning eHealth11/24/2014

Modern Healthcare, 11/21/2014